Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News argenx SE ARGX

argenx SE is a clinical stage biotechnology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Its product pipeline includes product candidates such as ARGX-111, ARGX-109, ARGX-115, ARGX-112, and others. The company operates in the Netherlands, Germany, Denmark, Belgium, Switzerland, the United States, and Luxembourg. It derives the majority of its revenues from Switzerland.


Recent & Breaking News (NDAQ:ARGX)

argenx announces launch of proposed global offering

GlobeNewswire February 1, 2021

argenx Announces "GO" Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis

GlobeNewswire February 1, 2021

argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline

GlobeNewswire January 8, 2021

argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China

GlobeNewswire January 6, 2021

argenx to Present at 39th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2021

argenx Enters Into Agreement To Acquire Priority Review Voucher

GlobeNewswire November 23, 2020

argenx Premieres A Mystery to Me, a Docuseries Inspired by the Myasthenia Gravis Patient Experience

PR Newswire November 17, 2020

argenx to Participate in Upcoming Virtual Investor Conferences

GlobeNewswire November 9, 2020

argenx Reports Third Quarter 2020 Financial Results and Provides Business Update

GlobeNewswire October 22, 2020

argenx to Report Third Quarter 2020 Financial Results and Business Update on October 22, 2020

GlobeNewswire October 15, 2020

argenx Expands Capabilities In Antibody Engineering Through Key Technology Partnerships

GlobeNewswire October 6, 2020

argenx Presents Additional Efgartigimod Data from Global Phase 3 ADAPT Trial at the Myasthenia Gravis Foundation of America 2020 Scientific Session

GlobeNewswire October 5, 2020

argenx Management to Present at Upcoming Virtual Investor Conferences

GlobeNewswire September 2, 2020

argenx to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference

GlobeNewswire August 4, 2020

argenx reports half year 2020 financial results and provides second quarter business update

GlobeNewswire July 30, 2020

argenx announces closing of global offering

GlobeNewswire June 1, 2020

argenx announces full exercise of underwriters' option to purchase additional ADSs

GlobeNewswire May 29, 2020

argenx raises $750 million in gross proceeds in a global offering

GlobeNewswire May 28, 2020

argenx announces launch of proposed global offering

GlobeNewswire May 26, 2020

argenx Announces Positive Topline Results from Phase 3 ADAPT Trial of Efgartigimod in Patients with Generalized Myasthenia Gravis

GlobeNewswire May 26, 2020